Eli Lilly’s shares surged more than 14% at the time, one of the company’s largest single-day gains in the last five years.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...

Lilly's late-stage results for its experimental oral obesity drug raised concerns.

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Hill-Lilly's departure comes as CT awaits another key child welfare role — leading the Office of the Child Advocate — to be filled.

After Eli Lilly & Co. shares fell sharply in the wake of disappointing trial data for its weight-loss pill, several of its executives and board members saw an opportunity to buy.

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.

If at first you don’t succeed, try, try again. | Texas Attorney General Ken Paxton and Health Choice Alliance are accusing Eli Lilly of “incentivizing” providers in the state to prescribe ...

Eli Lilly said it would raise drug prices in Europe to "make them lower" in U.S., though the actual impact on most patients abroad remains unclear.

Eli Lilly's oral weight loss pill showed promising results in trial but fell short compared to injectable drugs, prompting its stock price to drop 14 percent.

Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White House push to get drugmakers to raise medicine prices in Europe to ...